Sign Out
Ipratropium bromide and salbutamol sulphate inhaler has been used concomitantly with other drugs including sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of COPD. With the exception of salbutamol, there are no formal studies fully evaluating the interaction effects of ipratropium bromide and salbutamol sulphate inhaler and these drugs with respect to effectiveness.
Anticholinergic Agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications. Caution is therefore advised in the co-administration of Ipralin with other anticholinergic-containing drugs.
Beta-Adrenergic Agents: Caution is advised in the co-administration of Ipralin and other sympathomimetic agents due to increased risk of adverse cardiovascular effects. Beta-receptor blocking agents and salbutamol inhibit the effect of each other. Beta-receptor blocking agents should be used with caution in patients with hyperreactive airways.
Diuretics: The ECG changes and/or hypokalemia which may result from the administration of non-potassium sparing diuretics (eg, loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the co-administration of β-agonist-containing drugs eg, ipratropium bromide and salbutamol sulphate inhaler, with non-potassium sparing diuretics.
Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Ipratropium bromide and salbutamol sulphate inhaler should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of salbutamol on the cardiovascular system may be potentiated.
